Patients & Families

Nevanimibe Clinical Studies

Nevanimibe is an investigational drug being studied for the treatment of two orphan adrenal diseases: classic congenital adrenal hyperplasia (CAH) and endogenous Cushing’s syndrome.

Nevanimibe in Congenital Adrenal Hyperplasia (CAH):

Millendo initiated a Phase 2b trial of nevanimibe in CAH in July 2018. For more information please visit

Nevanimibe in Cushing’s syndrome:

A Phase 2 trial of nevanimibe for the treatment of patients with Cushing’s syndrome is ongoing. For more information please visit